ROMOSOZUMAB

Information current as at: 1 August 2025

PBAC meeting date: July 2022
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Evenity®
Pharmaceutical company:
Amgen Australia Pty Limited
Condition/indication:
(therapeutic use)
  • Osteoporosis
PBAC Submission type:
Change to PBS listing (Standard re-entry)
Comment:
--
Related medicines:

Progress Details

Submission received for:
July 2022 PBAC meeting
Opportunity for consumer comment:
Open 30/03/2022 and close 25/05/2022 (see PBS Website)
PBAC meeting:
Held on 06/07/2022
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
22/10/2022
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 09/11/2022
Status:
Finalised
Government processes:
Commenced on 09/11/2022
Medicine listed on the PBS:
01/02/2023 (see PBS schedule)

Case ID: a555

Page last updated: 30 June 2025

v.9.18